Vigil’s TREM2-Targeted Alzheimer’s Treatment Shows Early Promise, Moves On to Phase II
In a possible redemption for the TREM2 space in Alzheimer’s disease, Vigil Neuroscience announced positive early-stage data Thursday for its...
In a possible redemption for the TREM2 space in Alzheimer’s disease, Vigil Neuroscience announced positive early-stage data Thursday for its...